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Abstract
Information on the inﬂuence of pre-hospital antibiotic treatment on the causative organisms, clinical features and outcomes of patients with
community-acquired pneumonia (CAP) remains scarce. We performed an observational study of a prospective cohort of non-immuno-
suppressed adults hospitalized with CAP between 2003 and 2012. Patients were divided into two groups: those who had received
pre-hospital antibiotic treatment for the same episode of CAP and those who had not. A propensity score was used to match patients. Of
2179 consecutive episodes of CAP, 376 (17.3%) occurred in patients who had received pre-hospital antibiotic treatment. After propensity
score matching, Legionella pneumophila was more frequently identiﬁed in patients with pre-hospital antibiotic treatment, while Streptococcus
pneumoniae was less common (p <0.001 and p <0.001, respectively). Bacteraemia was less frequent in pre-treated patients (p 0.01). The
frequency of positive sputum culture and the sensitivity and speciﬁcity of the pneumococcal urinary antigen test for diagnosing
pneumococcal pneumonia were similar in the two groups. Patients with pre-hospital antibiotic treatment were less likely to present fever
(p 0.02) or leucocytosis (p 0.001). Conversely, chest X-ray cavitation was more frequent in these patients (p 0.04). No signiﬁcant
differences were found in the frequency of patients classiﬁed into high-risk Pneumonia Severity Index classes, in intensive care unit
admission, or in 30-day mortality between the groups. In conclusion, L. pneumophila occurrence was nearly three times higher in patients
who received pre-hospital antibiotics. After a propensity-adjusted analysis, no signiﬁcant differences were found in prognosis between study
groups. Pre-hospital antibiotic use should be considered when choosing aetiological diagnostic tests and empirical antibiotic therapy in
patients with CAP.
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Introduction
Although a large number of patients with community-acquired
pneumonia (CAP) require hospitalization, the majority are
treated as outpatients [1,2]. However, studies report that
around 10% of CAP patients initially treated as outpatients
require subsequent hospitalization [3,4]. Moreover, the
frequency of pre-hospital antibiotic use in hospitalized patients
with CAP ranges between 12 and 27% [5,6].
Recent studies have suggested that outpatient antibiotic
treatment for CAP may be associated with increased disease
severity and hospital complications, and may affect the
predictive value of inﬂammatory biomarkers [6,7]. Despite
this, however, the few studies published to date have been
limited by their exclusive use of database records [3,7],
retrospective analysis [8] or by the fact that they report the
effects of previous antibiotic treatment as a secondary ﬁnding
[6,9]. Moreover, they do not specify the type of antibiotic used
or state whether other confounding factors were considered.
Therefore, the information about the inﬂuence of pre-hospital
antibiotic treatment on the causative organisms, clinical
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features and outcomes of hospitalized patients with CAP
remains limited.
In this study we sought to determine the impact of
pre-hospital antibiotic treatment for the same episode of
CAP on causative organisms, clinical features and outcomes.
Methods
Setting, patients and study design
This observational study was conducted at a 700-bed teaching
hospital for adults in Barcelona, Spain. All non-severely
immunosuppressed patients admitted to the hospital with
CAP via the emergency department from 1 January 2003 to 31
December 2012 were prospectively recruited and followed.
Immunosuppressed patients (those with neutropenia, HIV
infection, transplantation, splenectomy, receiving immunosup-
pressants and/or >20 mg/day of prednisone or its equivalent)
and nursing home residents were excluded. The study was
approved by the Ethics Committee of the hospital. Written
informed consent was obtained from all patients before
enrolment.
For the purposes of this study, patients hospitalized with
CAP were divided into two groups: patients who had received
pre-hospital antibiotic treatment for the same episode of CAP
and patients who had not. The use of pre-hospital antibiotics
was recorded on admission, and three classes of antibiotic
drugs were investigated: b-lactams, macrolides and quinolones.
Follow-up
Patients were seen daily during the hospital stay by one or
more of the investigators, who recorded clinical data in a
computer-assisted protocol. Data were collected on demo-
graphic characteristics, comorbidities, causative organisms,
antibiotic susceptibilities, biochemical analysis, empirical anti-
biotic therapy, and outcomes, including mortality. The Pneu-
monia Severity Index (PSI) and CURB-65 were used to stratify
patients according to risk [10,11].
Deﬁnitions
Pre-hospital antibiotic treatment was deﬁned as the oral intake
of antibiotic drugs >24 h before hospitalization for the same
episode of acute disease. Patients were classiﬁed as receiving
antibiotics if they self-reported prescription of any of these
medications or by reviewing the prescriptions from their
general practitioner at the SAP Healthcare Database of the
Catalan Health Service (Institut Catala de la Salut).
Community-acquired pneumonia was deﬁned as an acute
illness associated with two or more of the following signs and
symptoms: new cough with or without sputum production,
pleuritic chest pain, dyspnoea, fever or hypothermia, altered
breath sounds on auscultation, leucocytosis, plus the presence
of a new inﬁltrate on a chest radiograph. Pneumococcal
pneumonia was diagnosed as deﬁned elsewhere [12].
The diagnosis of septic shock was based on a systolic blood
pressure of <90 mmHg and peripheral hypoperfusion with the
need for vasopressors. Time to clinical stability was deﬁned as
described elsewhere [13]. Early case-fatality rate and overall
case-fatality rate were deﬁned as death from any cause within
72 h and 30 days after hospital admission, respectively. All
patients were prospectively followed up during hospitalization.
In addition, a long-term follow-up visit took place 1 month
after discharge.
Microbiological studies
Pathogens in blood, pleural effusion, sputum and other samples
were investigated using standard microbiological procedures.
The Streptococcus pneumoniae antigen in urine was detected by
using a rapid immunochromatographic assay (NOW Assay;
Binax Inc., Portland, ME, USA). Legionella pneumophila Sero-
group 1 antigen in urine was detected by an immunochro-
matographic method (NOW Legionella Urinary Antigen Test;
Binax Inc.) or by ELISA (ELISA-Bartels, Bartels, Trinity Biotech,
Wicklow, Ireland). Serological methods were used both on
admission and 3–4 weeks thereafter, to determine antibodies
against the following pathogens: Mycoplasma pneumoniae,
Chlamydophila psittacci, Chlamydophila pneumoniae, Coxiella bur-
netii, L. pneumophila, respiratory syncytial virus, parainﬂuenza
virus and inﬂuenza A virus [14]. Real-time PCR was performed
to identify inﬂuenza A (H1N1)pdm09 virus.
Statistical analysis
Categorical variables were described using counts and per-
centages from the available data. Continuous variables were
expressed as the mean and SD or median and interquartile
range for abnormally distributed data (Kolmogorov–Smirnov
test). To detect signiﬁcant differences between study groups,
we used the chi-square test or Fisher’s exact test for
categorical variables and the Student’s t-test or Mann–Whitney
U-test for continuous variables, as appropriate.
To evaluate propensity, the probability that a patient had
received an antibiotic before hospital admission was assessed
with multivariate analysis. The variables included in this
multivariate analysis were the ones considered as factors that
might inﬂuence the decision to give outpatient antibiotic
treatment to patients with CAP. This multivariate model was
used to create a propensity score for each patient, repre-
senting the probability that a patient had received antibiotic
treatment during pre-hospital care. We then matched patients
who had received antibiotics before hospital admission and
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patients who had not with an identical propensity score (a
precision of ﬁve decimal points). This procedure provided two
cohorts that were well matched for the confounders
measured. The propensity score was used in two ways to
correct for baseline disparities between the study groups.
First, the authors compared causative organisms, clinical
features and outcomes between the matched patient groups
(univariate). Second, the authors conducted a multivariate
analysis for intensive care unit admission and 30-day mortality
among all patients adjusting for the propensity score within
the model.
A p value <0.05 was considered statistically signiﬁcant.
Bonferroni correction was used to adjust the signiﬁcance
levels for individual antibiotics (a = 0.016). All reported p
values are two-tailed. All statistical calculations were per-
formed using the Statistical Package for the Social Sciences
(Version SPSS 15.01s) for Windows.
Results
During the study period, 2179 consecutive episodes of CAP in
non-immunosuppressed patients were recorded, of which 376
(17.3%) occurred in patients who had received pre-hospital
antibiotic treatment. The most common pre-hospital antibiot-
ics administered were b-lactams in 233 (62%) patients,
followed by quinolones in 90 (24%) and macrolides in 29
(8%). Fifteen (4%) patients received more than one antibiotic
class before hospitalization, three patients (0.8%) received
other antibiotics and in six patients (1.6%) the antibiotic class
was not registered. The reasons for hospitalization in this
group of patients were persistent CAP symptoms despite
outpatient treatment in 288 patients, appearance of new CAP
symptoms in 91, respiratory failure in 131, hypotension in 14,
presence of pleural effusion in 76, and other condition not
related to the current CAP episode in 28.
Table 1 shows the demographic features of patients with
and without pre-hospital antibiotic treatment. Patients who
received pre-hospital antibiotic treatment were younger and
less likely to be heavy alcohol consumers. They also had fewer
chronic comorbidities, mainly diabetes mellitus and chronic
cardiac disease.
An aetiological diagnosis for CAP was more frequently
established in patients who had not received antibiotic
treatment before hospitalization. Table 2 shows the distribu-
tion of causative organisms in the study groups. Streptococcus
pneumoniae was the most frequent causative organism in
patients from both groups. Patients who received pre-hospital
antibiotic treatment presented more infections attributable to
L. pneumophila, mainly patients who had been receiving
b-lactams. Conversely, S. pneumoniae and Haemophilus inﬂuen-
zae were more frequently identiﬁed in patients who had not
received antibacterial drugs in the outpatient setting. Oral
penicillin and erythromycin resistance rates in S. pneumoniae
were more frequently documented in patients who had
received pre-hospital antibiotic treatment. Bacteraemia was
less common in pre-treated patients (15.6% versus 4.4%;
p <0.001), mainly in those who had received b-lactams (1%;
p <0.001).
Regarding clinical features (Table 3), patients with pre-hos-
pital antibiotic treatment were more likely to report cough,
headache and arthromyalgias and less likely to present fever at
admission. In addition, they also presented lower rates of
impaired consciousness, tachypnoea, tachycardia and septic
shock. These patients were also less likely to be classiﬁed into
high-risk PSI and CURB-65 classes. Laboratory data showed
that patients in the pre-hospital antibiotic treatment group had
less leucocytosis.
TABLE 1. Demographic features in
patients with and without pre-hos-
pital antibiotic treatment
Without
pre-hospital
antibiotics
n = 1803 (%)
With
pre-hospital
antibiotics
n = 376 (%) p value
b-Lactams
n = 233 (%)
Quinolones
n = 90 (%)
Macrolides
n = 29 (%)
Age, median (IQR),
years
69 (55–78) 64 (51–76) 0.005 62 (48–77)a 68 (54.5–75.5) 58 (46–73)
≥65 years old 1104 (61.2) 198 (52.7) 0.002 122 (52.4)a 51 (56.7) 13 (44.8)
Male sex 1246 (69.1) 247 (65.7) 0.19 153 (65.7) 61 (67.8) 17 (58.6)
Current Smoker 501 (27.9) 96 (25.6) 0.36 62 (26.7) 18 (20.0) 8 (27.6)
Alcohol abuse 324 (18.0) 52 (13.9) 0.05 31 (13.4) 13 (14.6) 8 (27.6)
Inﬂuenza vaccine 872 (52.6) 173 (50.4) 0.47 107 (50.2) 41 (50.0) 13 (50)
Pneumococcal vaccine 375 (23.6) 78 (23.4) 0.94 46 (22.2) 19 (23.8) 6 (24)
Comorbid conditions 1376 (76.4) 265 (70.5) 0.01 165 (70.8) 61 (67.8) 22 (75.9)
COPD 542 (30.1) 106 (28.2) 0.47 59 (25.3) 33 (36.7) 8 (27.6)
Diabetes mellitus 413 (22.9) 65 (17.3) 0.01 40 (17.2) 17 (18.9) 5 (17.2)
Chronic heart disease 414 (23.0) 71 (18.9) 0.08 49 (21.1) 12 (13.3) 5 (17.2)
Chronic renal disease 177 (9.8) 31 (8.2) 0.34 21 (9.0) 7 (7.8) 3 (10.3)
Chronic liver disease 132 (7.3) 23 (6.1) 0.40 9 (3.9) 8 (8.9) 3 (10.3)
COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
Data are number and % unless otherwise indicated.
aA p value <0.05 was considered statistically signiﬁcant. Bonferroni correction was used to adjust the signiﬁcance levels
for individual antibiotics (a = 0.016).
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As detailed in Table 4, patients with pre-hospital antibiotic
treatment were less likely to present complications during
hospitalization or to require admission to the intensive care
unit. Similarly, patients with pre-hospital antibiotic treatment
had a shorter time to clinical stability, although there was no
difference in length of hospital stay. There was a non-signiﬁcant
difference in mortality between study groups.
Propensity score analysis
The propensity score was generated using 13 variables
(Table 5). With this model, 150 patients in the pre-hospital
antibiotic group were matched to 416 patients in the other
study group with a precision of ﬁve decimal points. Legionella
pneumophila was more frequent in patients with pre-hospital
antibiotic treatment and S. pneumoniae was less common
Without
pre-hospital
antibiotics
n = 1803 (%)
With
pre-hospital
antibiotics
n = 376 (%) p value
b-Lactams
n = 233 (%)
Quinolones
n = 90 (%)
Macrolides
n = 29 (%)
Streptococcus pneumoniaeb 822 (45.6) 92 (24.5) <0.0001 41 (17.6)c 30 (33.3) 11 (37.9)
Legionella pneumophila 68 (3.8) 34 (9.0) <0.0001 27 (11.6)c 2 (2.2) 4 (13.8)
Haemophilus inﬂuenzaeb 93 (5.2) 10 (2.7) 0.03 4 (1.7) 2 (2.2) 3 (10.3)
Aspiration pneumoniad 96 (5.3) 19 (5.1) 0.83 15 (6.4) 4 (4.4) 0 (0)
Gram-negative bacilli 37 (2.1) 9 (2.4) 0.67 4 (1.7) 4 (4.4) 0 (0)
Pseudomonas aeruginosa 26 (1.4) 7 (1.9) 0.54 2 (0.9) 4 (4.4) 0 (0)
Atypical agentse 56 (3.1) 14 (3.7) 0.53 13 (5.6) 1 (1.1) 0 (0)
Virus 75 (4.2) 12 (3.2) 0.38 6 (2.6) 3 (3.3) 2 (6.9)
Inﬂuenza A
(H1N1)pdm09
68 (3.8) 10 (2.7) 0.36 5 (2.1) 2 (2.2) 2 (6.9)
Mixed aetiologyf 101 (5.6) 7 (1.9) 0.002 3 (1.3)c 2 (2.2) 1 (3.4)
No pathogen identiﬁed 578 (32.1) 180 (47.9) <0.0001 120 (51.5)c 41 (45.6)c 9 (31.0)
Data are number and % unless otherwise indicated.
aSputum cultures were performed in 826 patients (37.9%), blood cultures in 1902 (87.3%), pleural effusion cultures in 158
(7.2%), pneumococcal urinary antigen test in 1882 (86.4%), L. pneumophila Serogroup 1 antigen in urine in 1133 (52%) and
serology in 546 (25.1%).
bOral penicillin resistance and erythromycin resistance rates were more frequently documented in patients who had
received pre-hospital antibiotic treatment (9.8% versus 25%, p 0.04 and 14.8% versus 40%, p 0.008; respectively). Among
H. inﬂuenzae strains, no signiﬁcant differences in the prevalence of b-lactamase production were detected between
groups.
cBonferroni correction was used to adjust the signiﬁcance levels for individual antibiotics (a = 0.016).
dAspiration pneumonia was diagnosed on a clinical and radiological basis in patients who had risk factors such as
compromised consciousness, altered gag reﬂex, dysphagia, severe periodontal disease, putrid sputum and radiographic
evidence of involvement of a dependent pulmonary segment or necrotizing pneumonia.
eMycoplasma pneumoniae, Chlamydophila psittacci, Chlamydophila pneumoniae, Coxiella burnetii.
fMixed aetiology was deﬁned as community-acquired pneumonia due to more than one pathogen.
TABLE 2. Causative organisms in
patients with and without pre-hospi-
tal antibiotic treatmenta
Without
pre-hospital
antibiotics
n = 1803 (%)
With
pre-hospital
antibiotics
n = 376 (%) p value
b-Lactams
n = 233 (%)
Quinolones
n = 90 (%)
Macrolides
n = 29 (%)
Headache 258 (14.3) 84 (22.3) <0.0001 56 (24.0)a 20 (22.2) 4 (13.8)
Arthralgias 383 (21.3) 97 (25.8) 0.05 58 (24.9) 19 (21.1) 9 (31.0)
Cough 1505 (83.7) 340 (90.4) 0.001 208 (89.3) 81 (90.0) 28 (96.6)
Purulent sputum 761 (44.8) 172 (48.3) 0.22 104 (47.9) 40 (46.0) 15 (53.6)
Pleuritic chest pain 768 (42.6) 157 (42.0) 0.81 92 (39.7) 51 (56.7)a 7 (25.0)
Fever 774 (43.4) 125 (33.6) 0.001 76 (32.8)a 29 (32.6) 10 (37.0)
Tachycardia
(heart rate ≥100)
917 (51.2) 151 (40.7) <0.0001 90 (39.9)a 39 (43.3) 13 (46.4)
Tachypnoea
(respiratory rate ≥30)
721 (46.4) 116 (37.4) 0.004 64 (33.5)a 30 (40.5) 12 (50.0)
Impaired consciousness 251 (13.9) 32 (8.5) 0.004 17 (7.3)a 9 (10.0) 3 (10.3)
Septic shock 198 (11.0) 16 (4.3) <0.0001 8 (3.4)a 5 (5.6) 1 (3.4)
Pleural effusion 318 (17.7) 70 (18.6) 0.67 39 (16.7) 22 (24.4) 4 (13.8)
Multilobar pneumonia 563 (31.5) 128 (34.0) 0.32 86 (36.9) 21 (23.3) 11 (37.9)
Chest X-ray cavitation 23 (1.3) 13 (3.5) 0.003 8 (3.4) 4 (4.4) 0 (0)
Leucocytosis (white
blood cell ≥12000)
1115 (61.9) 198 (52.7) 0.001 117 (50.2)a 56 (62.2) 14 (48.3)
Respiratory failure
(PaO2/FiO2 <300)
870 (70.2) 167 (66.3) 0.22 109 (67.7) 35 (57.4) 13 (81.3)
PSI high risk classesb 1086 (60.3) 177 (47.1) <0.0001 109 (46.8)a 40 (44.4)a 16 (55.2)
CURB-65 high risk
classesb
1088 (63.4) 170 (47) <0.0001 101 (47)a 47 (54) 13 (50)
PSI, pneumonia severity index.
Data are number and % unless otherwise indicated.
aA p value <0.05 was considered statistically signiﬁcant. Bonferroni correction was used to adjust the signiﬁcance levels
for individual antibiotics (a = 0.016).
bPatients were stratiﬁed into the following risk classes according to the PSI score: low risk (≤90 points, classes I, II, and
III) and high risk (>90 points, classes IV and V). Patients were stratiﬁed into the following risk classes according to their
CURB-65 score: low risk (0–1 point) and high risk (>1 point).
TABLE 3. Clinical features at
admission in patients with and with-
out pre-hospital antibiotic treat-
ment
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(p <0.001 and p <0.001, respectively). Patients with pre-hos-
pital antibiotic treatment presented less fever (p 0.02), leuc-
ocytosis (p 0.001) and bacteraemia (p 0.01). The frequency of
positive sputum culture was similar in the two groups (97 of
168 (44.2%) versus 19 of 43 (57.7%); p 0.11) as were the
sensitivity and speciﬁcity of the pneumococcal urinary antigen
test used for diagnosing pneumococcal pneumonia (85.2%
versus 90.3% and 98.1% versus 99.1%, respectively) or
bacteraemic pneumococcal pneumonia (78.5% versus 75%
and 92% versus 100%). No signiﬁcant differences in the
S. pneumoniae resistance patterns were documented. Con-
versely, chest X-ray cavitation was more frequent in the
pre-hospital antibiotic treatment group (p 0.04). No signiﬁcant
differences were found in the frequency of patients classiﬁed
into high-risk CAP-speciﬁc scores, intensive care unit admis-
sion or 30-day mortality between study groups.
When the propensity score was entered into the multivar-
iate models, the pre-hospital antibiotic use was not signiﬁcantly
associated with intensive care unit admission and 30-day
mortality (OR 0.74, 95% CI 0.33–1.66 and OR 2.69, 95% CI
0.77–9.08, respectively).
Discussion
The demographic features of patients with pre-hospital
antibiotic treatment in our cohort were similar to those
previously reported: that is, these patients were signiﬁcantly
younger and had lower rates of comorbidity than the other
group. These demographic differences are probably because
clinicians reserve in-hospital treatment for older and more
compromised patients. In addition, the current CAP severity
scores used to assess the need for hospitalization attach great
importance to age and the presence of comorbidities. These
variables are an obstacle to obtaining valid results unless they
and other confounding factors are carefully controlled. Signif-
icantly, previous studies have not studied the propensity for
prescribing pre-hospital antibiotic therapy.
We compared the clinical picture of CAP at admission in
patients who received and who did not receive pre-hospital
antibiotic treatment. Although CAP occurs regularly in both
groups, with purulent sputum, pleuritic pain and signs of
consolidation, the groups present differences with regard to
other clinical features. Patients who received pre-hospital
antibiotic treatment presented more headache and arthralgias,
and less fever at admission. Likewise, regarding radiographic
ﬁndings, we found that patients with pre-hospital antibiotic
treatment more frequently had chest X-ray cavitation. Previ-
ous studies offer little information on the clinical presentation
of CAP in this context.
Moreover, we observed that patients receiving prior
antibiotics were less likely to have fever and leucocytosis.
Hence, it is plausible to think that prior use of antibiotics may
lead to a blunted inﬂammatory response at admission. In this
regard, in a cohort of CAP patients Kr€uger et al. [6]
demonstrated that procalcitonin, C-reactive protein and white
blood cell count are not good predictors of mortality in
patients who have received pre-hospital antibiotic treatment.
This ﬁnding suggests caution in interpreting the diagnostic and
TABLE 4. Outcomes in patients with and without pre-hospital antibiotic treatment
Without
pre-hospital
antibiotics
n = 1803 (%)
With
pre-hospital
antibiotics
n = 376 (%) p value
b-Lactams
n = 233 (%)
Quinolones
n = 90 (%)
Macrolides
n = 29 (%)
In-hospital complications 560 (31.2) 86 (22.9) 0.001 55 (23.6) 21 (23.6) 5 (17.2)
ICU admission 213 (11.9) 24 (6.4) 0.002 16 (6.9) 4 (4.5) 2 (6.8)
MV and/or NIMV 186 (10.5) 19 (5.1) 0.001 13 (5.7) 4 (4.5) 1 (3.6)
Length of intravenous therapy (days),
median (IQR)
4 (2–7) 4 (2–7) 0.07 4 (2–7) 4 (2–8) 2.5 (2–4)
Time to clinical stability, median (IQR) 3 (2–6) 3 (2–5) 0.04 4 (2–5) 3 (1–6) 2 (1–4)
Length of hospital stay, median (IQR) 7 (5–11) 7 (5–10.5) 0.54 7 (6–10) 8.5 (5–12) 6 (5–7)a
Early case-fatality rate (≤72 h) 22 (1.2) 4 (1.1) 1 3 (1.3) 1 (1.1) 0 (0)
Overall case-fatality rate (≤30 days) 86 (4.8) 21 (5.6) 0.50 11 (4.7) 8 (8.9) 1 (3.4)
ICU, intensive care unit; IQR, interquartile range; MV, mechanical ventilation; NIMV, non-invasive mechanical ventilation.
Data are number and % unless otherwise indicated.
aA p value of <0.05 was considered statistically signiﬁcant. Bonferroni correction was used to adjust the signiﬁcance levels for individual antibiotics (a = 0.016).
TABLE 5. Logistic regression model for derivation of the
propensity score
Variable Coefﬁcient OR (95% CI) p value
Age (>64 years old) 0.397 0.67 (0.44–1.02) 0.06
Male sex 0.070 0.93 (0.65–1.33) 0.69
Comorbidities 0.224 0.79 (0.52–1.21) 0.29
Current smoker 0.162 0.85 (0.55–1.30) 0.45
Alcohol abuser 0.161 0.85 (0.52–1.37) 0.50
Seasonal inﬂuenza
vaccination
0.251 1.28 (0.84–1.94) 0.23
Pneumococcal vaccination 0.010 1.01 (0.66–1.52) 0.96
Purulent sputum 0.093 1.09 (0.79–1.50) 0.56
Altered mental status at
admission
0.348 0.70 (0.38–1.30) 0.29
Septic shock at admission 1.217 0.29 (0.11–0.74) 0.01
Tachycardia at admission 0.471 0.62 (0.44–0.87) 0.006
Tachypnoea at admission 0.331 0.71 (0.51–1.01) 0.05
Respiratory failure (PaO2/
FiO2 <300) at admission
0.016 1.01 (0.71–1.44) 0.93
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predictive values of inﬂammatory markers in CAP patients
with antibiotic treatment prior to hospital admission.
An important ﬁnding in our study was the difference in the
frequency of causative organisms of CAP between the study
groups. The prevalence of L. pneumophila was nearly three
times higher in patients who received pre-hospital antibiotics,
mainly b-lactams. Furthermore, we did not ﬁnd differences in
the proportion of other potentially resistant organisms, such
as Pseudomonas aeruginosa, between the study groups. As
expected, bacteraemia was less frequent in patients pre--
treated with antibiotics and we also found a higher proportion
of unknown aetiology in this group of patients. Interestingly,
the frequency of positive sputum culture was comparable in
the two groups. The sensitivity and speciﬁcity of the pneumo-
coccal urinary antigen test for diagnosing pneumococcal
pneumonia was also similar. Therefore, information on
pre-hospital antibiotic treatment should always be recorded
because it can guide the choice of aetiological diagnostic tests
and the empirical antibiotic therapy to be used in patients with
CAP. In fact, the current Infectious Diseases Society of
America/American Thoracic Society guidelines provide rec-
ommendations for using aetiological evidence in this group of
patients [1], although they are still to be validated.
In the propensity analysis, we did not ﬁnd signiﬁcant
differences in prognosis between study groups. In contrast,
Johnson et al. [15] found decreased in-hospital mortality
associated with antibiotic treatment before hospitalization,
while van de Garde et al. [7] and Marrie and Wu [16] showed
increased in-hospital mortality in this group of patients.
However, these studies did not control for confounding factors.
Interestingly, we found that patients who required hospitaliza-
tion after attempted outpatient treatment had a higher mortal-
ity rate than is normally expected in the outpatient setting [17].
The strengths of the current study include the prospective
nature of the cohort, the large number of hospitalized patients
with CAP, and the comprehensive data collection. In addition,
this is the ﬁrst study to perform a widespread analysis of the
impact of pre-hospital admission antibiotic use on the clinical
presentation and outcomes of CAP. We also performed a
propensity analysis to control for confounding factors. Nev-
ertheless, there are some limitations that should be acknowl-
edged. First, the study was conducted at a single Spanish centre
and we do not know whether the results can be extrapolated
to other settings. Second, this is an observational study and we
could not eliminate unmeasured confounders between study
groups. Third, we were unable to verify outpatient diagnosis
and time of antibiotic administration before hospitalization in
all patients. Finally, because of the small sample size of patients
who receive individual antibiotics, our data for these groups
should be interpreted with caution.
In conclusion, after controlling for confounding factors in a
propensity analysis, patients who received pre-hospital antibi-
otic treatment presented distinct clinical features from those
who did not. In addition, the prevalence of L. pneumophila was
nearly three times higher in patients who received pre-hospital
antibiotics, mainly b-lactams. Bacteraemia was less frequent in
patients pre-treated with antibiotics. No signiﬁcant differences
were found in the prognosis between study groups. Informa-
tion about pre-hospital antibiotics use can help to guide the
choice of aetiological diagnostic tests and the empirical
antibiotic therapy to be used in patients with CAP.
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